Citation: Cd (Clinical Diabetes). 36(2):138-147, 2018 Apr.Journal: Clinical diabetes : a publication of the American Diabetes Association.Published: 2018ISSN: 0891-8929.Full author list: Aroda VR; Arulandu JR; Cannon AJ.UI/PMID: 29686453.Institution(s): MedStar Health Research InstituteActivity type: Journal Article.Medline article type(s): Journal ArticleDigital Object Identifier: https://dx.doi.org/10.2337/cd17-0065 (Click here)Abbreviated citation: CLIN DIABETES. 36(2):138-147, 2018 Apr.Abstract: <b>IN BRIEF</b> Given the progressive nature of type 2 diabetes, treatment intensification is usually necessary to maintain glycemic control. However, for a variety of reasons, treatment is often not intensified in a timely manner. The combined use of basal insulin and a glucagon-like peptide-1 receptor agonist is recognized to provide a complementary approach to the treatment of type 2 diabetes. This review evaluates the efficacy and safety of two co-formulation products, insulin degludec/liraglutide and insulin glargine/lixisenatide, for the treatment of type 2 diabetes inadequately controlled on either component agent alone. We consider the benefits and limitations of these medications based on data from randomized clinical trials and discuss how they may address barriers to treatment intensification.